Vaccine and Treatment Evaluation Units (VTEU)
$5,921,655UM1FY2020AINIH
Baylor College Of Medicine, Houston TX
Investigators
Linked publications & trials
Paper 39774938Paper 39158584Paper 39040211Paper 38518789Paper 38408357Paper 38332733Paper 37561027Paper 37451878Paper 37440227Paper 37433788Paper 37383244Paper 37330602Paper 36895286Paper 36442063Paper 35898343Paper 35818363Paper 35798000Paper 35785530Paper 35734087Paper 35675078Paper 35544369Paper 35535503Paper 35145311Paper 35081298Paper 35081293Paper 34931200Paper 34910859Paper 34812653Paper 34672949Paper 34671773Paper 34409989Paper 34379740Paper 34278310Paper 33306283Paper 32445440
Abstract
ABSTRACT This supplement request is for a Phase 3, randomized, stratified, observer-blind, placebo- controlled study to evaluate the efficacy, safety and immunogenicity, of mRNA-1273 vaccine compared to placebo in adults 18 years of age and older who have no known history of SARS- CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2 infection. This request also relates to other COVID 19 activities.
View original record on NIH RePORTER →